Kexing Biopharm’s Generic Paclitaxel (Albumin-bound) Approved in Uruguay

Article source：Kexing BiopharmOct 31,2025View： 80

Recently, Kexing Biopharm (stock code: 688136.SH) , in collaboration with Haichang Biotech, which that its Generic Paclitaxel for Injection (Albumin-bound) has received marketing authorization from the Ministry of Public Health (MSP) of Uruguay. This approval marks a key milestone in expanding access to oncology therapies across Latin America.

Uruguay, known for its EU-aligned pharmaceutical standards and strategic geographic position, serves as a regional logistics hub for the Latin American pharmaceutical industry. Recognized globally as a frontline treatment recommended by international oncology guidelines, Generic Paclitaxel (Albumin-bound) has demonstrated a favorable safety profile and strong clinical acceptance. The approval of Generic Paclitaxel (Albumin-bound) further supports Kexing’s strategy to strengthen its commercial footprint and regulatory presence across the region.

Kexing Biopharm will continue to advance its “Global Selection + Global Coverage” strategy, partnering with international collaborators to expand product registration and commercialization, and to deliver broader treatment access to patients worldwide.